Welcome to our dedicated page for Owlet SEC filings (Ticker: OWLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Owlet, Inc. (NYSE: OWLT) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI‑assisted summaries to help interpret complex documents. As a pediatric health platform offering FDA‑cleared medical and consumer pediatric wearables and connected cameras, Owlet’s filings give investors insight into how it manages growth, regulation, financing, and governance.
In Owlet’s Form 8‑K filings, readers can find information on quarterly financial results, equity offerings, warrant exchanges, executive leadership changes, corporate governance amendments, and settlements related to historical product matters. Recent 8‑Ks describe preliminary and final financial results, an underwriting agreement for a follow‑on equity offering, a warrant‑for‑share exchange approved by stockholders, and updates to the company’s certificate of incorporation and incentive award plan.
Definitive proxy statements (such as the DEF 14A) outline board structure, director elections, equity compensation plans, auditor ratification, and proposals requiring stockholder approval. These documents also discuss topics like officer exculpation provisions, stock issuance approvals, and the mechanics of Owlet’s annual meeting, giving a detailed view of the company’s governance framework.
On this page, you can monitor new 10‑K annual reports and 10‑Q quarterly reports as they are filed with EDGAR, along with any additional 8‑Ks and amendments. Stock Titan’s AI features summarize key sections, highlight risk factor themes, capital structure changes, and major contract disclosures, and surface notable items such as warrant exchanges or derivative litigation settlements. You can also review insider‑related information disclosed in connection with equity plans and exchanges, and track how Owlet describes regulatory, reimbursement, and market risks associated with its pediatric monitoring devices and digital health services.
Owlet, Inc. filed its Q3 2025 10‑Q reporting stronger top‑line and improved profitability. Revenue reached $31,988 thousand versus $22,122 thousand a year ago, lifting gross profit to $16,200 thousand. Operating income was $1,216 thousand, compared with a loss last year, and net income totaled $4,134 thousand, aided by a common stock warrant liability adjustment.
Cash and cash equivalents were $23,760 thousand. The company reported $18,616 thousand outstanding under its asset‑based line of credit and $7,500 thousand drawn on its WTI term loan. Total liabilities were $113,464 thousand and stockholders’ deficit was $54,143 thousand as of September 30, 2025. As a subsequent event, the company completed an offering of 4,825,400 shares at $7.15 per share, yielding net proceeds of $32,109 thousand. Shares outstanding were 27,580,607 as of November 10, 2025.
The filing states conditions that raise substantial doubt about the company’s ability to continue as a going concern, despite a profitable quarter and the October equity raise.
Owlet, Inc. (OWLT) furnished a press release announcing its financial results for the three months ended September 30, 2025 and noting related management changes. The company provided the release as Exhibit 99.1 to a Form 8-K.
The information was furnished under Item 2.02 and, as stated, is not deemed “filed” under the Exchange Act. The filing also lists the cover page Inline XBRL data as Exhibit 104. Owlet’s Class A common stock trades on the NYSE under the symbol OWLT, and the company is identified as an emerging growth company.
Owlet, Inc. launched an underwritten public offering of 4,196,000 shares of Class A common stock at $7.15 per share, with a 30‑day option for underwriters to purchase up to 629,400 additional shares. The company said it intends to use the net proceeds to support continued commercialization, research and development, and for general corporate purposes. Directors, executive officers, and certain stockholders agreed to a 90‑day lock‑up after the date of the final prospectus.
Owlet also provided preliminary unaudited third‑quarter 2025 results: revenue is estimated at $30 million to $32 million, up from $22.1 million a year ago. Estimated gross margin is approximately 49.5%–51% versus 52.2% in the prior‑year period, which the company believes reflects tariff impacts on cost of goods sold. Cash and cash equivalents were approximately $23.8 million as of September 30, 2025 and include about $18.6 million in additional borrowings during the quarter under its asset‑based revolving credit facility.
Owlet, Inc. is offering 4,196,000 shares of Class A common stock at $7.15 per share. The deal implies a gross offering size of $30,001,400, with underwriting discounts of $1,950,091 and estimated net proceeds of $27.4 million after expenses. The underwriters have a 30‑day option to purchase up to 629,400 additional shares. Shares are expected to be delivered on or about October 23, 2025.
Owlet’s stock trades on the NYSE as “OWLT.” The company plans to use proceeds to support continued commercialization, research and development, and general corporate purposes. After the offering, common stock outstanding would be 25,880,584 shares (or 26,509,984 if the option is exercised in full). The filing notes an immediate dilution to new investors of $5.91 per share.
Recent developments include the issuance of 5,426,429 shares in a warrant exchange with a 180‑day lockup, and preliminary Q3 2025 results: revenue estimated at $30–$32 million (vs. $22.1 million a year ago), gross margin of approximately 49.5%–51% (vs. 52.2%), and cash and equivalents of $23.8 million including $18.6 million in additional revolver borrowings.
Owlet, Inc. (OWLT) launched a primary offering of Class A common stock via a preliminary prospectus supplement on the NYSE. The company plans to grant underwriters a 30‑day option to purchase additional shares, with proceeds to support continued commercialization, research and development, and general corporate purposes.
Owlet reported preliminary Q3 2025 results: revenue of $30–$32 million versus $22.1 million a year ago; gross margin of 49.5%–51% versus 52.2% last year, reflecting tariff impacts on cost of goods sold; and cash and cash equivalents of $23.8 million, including $18.6 million of additional borrowings under its asset‑based revolver. On October 10, 2025, the company issued 5,426,429 shares in a warrant exchange, subject to a 180‑day lockup.
Shares outstanding were 16,258,155 as of June 30, 2025, after giving effect to the warrant exchange. The stock last closed at $8.80 on October 20, 2025.
Owlet, Inc. (OWLT) reported an insider ownership change. On 10/10/2025, a director exchanged 131,195 warrants for 80,235 shares of Class A common stock at a ratio of approximately 0.61 shares per warrant (Transaction Codes: A for shares acquired, D for warrants disposed).
The warrants were initially issued in February 2023 in connection with the Company’s Series A Convertible Preferred Stock. Following the transaction, the director beneficially owns 419,004 shares directly and holds 0 warrants. The warrants carried a $4.44 exercise price; the filing lists a $0 price for the derivative security exchange.
Owlet, Inc. (OWLT): Director Form 4 filing — On 10/10/2025, a director acquired 107,626 shares of Class A common stock. Following the transaction, the director beneficially owns 233,030 shares, held directly.
The shares were issued in exchange for previously held warrants tied to the company’s Series A (February 2023) and Series B (February 2024) preferred financings, at approximate exchange ratios of 0.61 and 0.56 shares per warrant. Two warrant positions for 131,195 and 48,621 underlying shares were disposed, leaving zero derivative securities.
Owlet, Inc. (OWLT): A reporting person acquired 686,469 shares of common stock on October 10, 2025 via an exchange of previously issued warrants and now directly owns 1,567,468 shares.
The transaction exchanged warrants issued in connection with the company’s Series A and Series B financings for common shares at approximate ratios of 0.61 and 0.56 shares per warrant, respectively. Specifically, 712,915 warrants initially issued on 02/17/2023 (expiring 02/17/2028) and 444,601 warrants initially issued on 02/29/2024 (expiring 03/01/2029) were converted (Transaction Code C). Following the exchange, the reported balance of these derivative securities is 0.
Trilogy Equity Partners filed Amendment No. 4 to its Schedule 13D on Owlet, Inc. (Class A Common Stock), reporting beneficial ownership of 2,022,178 shares, or approximately 8.7% of the class.
The reported stake consists of 1,567,468 common shares, plus 158,309 shares issuable upon conversion of Series A Convertible Preferred and 296,401 shares issuable upon conversion of Series B Convertible Preferred, as disclosed. Owlet had 22,788,420 shares outstanding as of October 10, 2025.
Trilogy has sole voting and dispositive power over the reported shares. On October 10, 2025, Trilogy exchanged 712,915 Series A-related warrants and 444,601 Series B-related warrants for common shares at exchange ratios of 0.61 and 0.56 shares per warrant, respectively.
Owlet, Inc. (OWLT) received an amended Schedule 13D (Amendment No. 5) from Eclipse-affiliated funds and Lior Susan, updating beneficial ownership and disclosing a completed warrant-for-share exchange. On
Reported beneficial holdings include: Eclipse Continuity Fund I at 1,066,472 shares (4.7%), Eclipse Ventures Fund I at 968,694 shares (4.3%), and Eclipse Early Growth Fund I at 7,621,469 shares (30.8%), which includes 1,955,800 shares issuable upon preferred stock conversion. Lior Susan is reported at 9,656,635 shares (40.5%). Percentages reference 22,788,420 Class A shares outstanding as of